Tom Huizinga

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/973247/publications.pdf

Version: 2025-02-01

680 peer-reviewed articles	56,968 peer-reviewed citations	1741 100 peer-reviewed h-index	426041 4.19 score
741 documents	63322 doc citations	2150 105 h-index	80522 citing authors

#	Article	IF	Citations
1	Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies. Rheumatology, 2025, 64, 1052-1059.	1.4	13
2	Multitiered Proteome Analysis Displays the Hyperpermeability of the Rheumatoid Synovial Compartment for Plasma Proteins. Molecular and Cellular Proteomics, 2025, 24, 100900.	3.2	4
3	Distinct clinical outcomes based on multiple serum cytokine and chemokine profiles rather than autoantibody profiles and ultrasound findings in rheumatoid arthritis: a prospective ultrasound cohort study. RMD Open, 2025, 11, e005163.	2.7	5
4	Rheumatoid arthritis-associated cervical spine deformity and flares in disease activity. Brain and Spine, 2025, 5, 104235.	0.2	1
5	Variable domain glycosylation as a marker and modulator of immune responses: Insights into autoimmunity and B-cell malignancies. Seminars in Immunology, 2025, 78, 101946.	5.7	4
6	Prolonged glucocorticoid use and rheumatoid arthritis-associated cervical spine deformity. Clinical Rheumatology, 2025, 44, 1919-1926.	1.3	1
7	Rheumatoid arthritis-associated interstitial lung disease in countries across the world. Seminars in Arthritis and Rheumatism, 2025, 73, 152719.	1.9	4
8	Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2025, 84, 1301-1312.	6.5	12
9	Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus. Journal of Autoimmunity, 2025, 154, 103438.	3.8	12
10	Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?. Annals of the Rheumatic Diseases, 2024, 83, 65-71.	6.5	17
11	IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2024, 83, 267-270.	6.5	8
12	Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort. Annals of the Rheumatic Diseases, 2024, 83, 161-168.	6.5	13
13	Can Pharmacological Conditioning as an Add-On Treatment Optimize Standard Pharmacological Treatment in Patients with Recent-Onset Rheumatoid Arthritis? A Proof-of-Principle Randomized Clinical Trial. Pharmaceuticals, 2024, 17, 110.	3.3	0
14	Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2024, 50, 817-828.	1.9	12
15	Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis. Nature Communications, 2024, 15, .	10.8	28
16	Does a history of smoking increase the risk of developing systemic sclerosis? Insights from the Leiden Combined Care in Systemic Sclerosis cohort. Rheumatology Advances in Practice, 2024, 8, .	0.7	0
17	Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study. RMD Open, 2024, 10, e004246.	2.7	6
18	Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort. RMD Open, 2024, 10, e004101.	2.7	5

#	Article	IF	Citations
19	Troponin I levels in systemic sclerosis patients with myocardial involvement. Journal of Scleroderma and Related Disorders, 2024, 9, 185-191.	0.6	2
20	Detection of Systemic Sclerosis-associated Interstitial Lung Disease by Exhaled Breath Analysis Using Electronic Nose Technology. American Journal of Respiratory and Critical Care Medicine, 2024, 210, 512-514.	5.0	6
21	Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study. RMD Open, 2024, 10, e004382.	2.7	4
22	Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open, 2024, 10, e004278.	2.7	21
23	Infliximab biosimilar GP1111: a review of 5 years' post-approval experience. Expert Opinion on Biological Therapy, 2024, 24, 615-625.	1.9	2
24	Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response. RMD Open, 2024, 10, e004411.	2.7	4
25	Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus. European Journal of Immunology, 2024, 54, .	2.2	3
26	Pathogenic role of anti-nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases. Immunological Reviews, 2024, 328, 265-282.	5.8	7
27	Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis. Journal of Autoimmunity, 2024, 149, 103320.	3.8	10
28	A genome-wide association analysis reveals new pathogenic pathways in gout. Nature Genetics, 2024, 56, 2392-2406.	14.1	88
29	Is AI-assisted active learning software able to reliably speed-up systematic literature reviews in rheumatology? A real-time comparison of AI-assisted and manual abstract selection. RMD Open, 2024, 10, e005024.	2.7	2
30	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	0.6	4
31	The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology, 2023, 62, SI74-SI81.	1.4	9
32	High Prevalence but Low Impact of Cognitive Dysfunction on Quality of Life in Patients With Lupus and Neuropsychiatric Symptoms. Arthritis Care and Research, 2023, 75, 1017-1025.	2.2	12
33	Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis. Seminars in Arthritis and Rheumatism, 2023, 58, 152136.	1.9	15
34	Mouth opening in systemic sclerosis: Its course over time, determinants and impact on mouth handicap. Journal of Scleroderma and Related Disorders, 2023, 8, 64-71.	0.6	6
35	Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis. Expert Review of Clinical Immunology, 2023, 19, 217-225.	2.3	9
36	Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2023, 82, 468-475.	6.5	21

#	Article	IF	Citations
37	Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment. RMD Open, 2023, 9, e002552.	2.7	8
38	Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies. RMD Open, 2023, 9, e002827.	2.7	7
39	Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison. Rheumatology and Therapy, 2023, 10, 539-550.	1.7	1
40	Patterns of clinical joint inflammation in juvenile idiopathic arthritis. RMD Open, 2023, 9, e002941.	2.7	10
41	Whole body insulin sensitivity is increased in systemic sclerosis. PLoS ONE, 2023, 18, e0283283.	1.5	7
42	Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort. RMD Open, 2023, 9, e002971.	2.7	10
43	Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial. RMD Open, 2023, 9, e002995.	2.7	2
44	The long-term course of the Health Assessment Questionnaire in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2023, 8, 192-202.	0.6	4
45	Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis. RMD Open, 2023, 9, e003148.	2.7	16
46	Anti-carbamylated protein antibodies in systemic sclerosis. Arthritis Research and Therapy, 2023, 25, .	2.9	2
47	Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open, 2023, 9, e003480.	2.7	10
48	Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos. Acta Clinica Belgica, 2022, 77, 233-240.	0.6	5
49	Evolution of Systemic Sclerosis–Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide. Arthritis Care and Research, 2022, 74, 433-441.	2.2	20
50	Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. Annals of the Rheumatic Diseases, 2022, 81, e69.	6.5	26
51	Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course. Annals of the Rheumatic Diseases, 2022, 81, 169-174.	6.5	31
52	Neuropsychiatric systemic lupus erythematosus is associated with a distinct type and shape of cerebral white matter hyperintensities. Rheumatology, 2022, 61, 2663-2671.	1.4	14
53	A framework for employing longitudinally collected multicenter electronic health records to stratify heterogeneous patient populations on disease history. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 761-769.	3.3	12
54	To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2022, 9, e000629.	1.6	2

#	Article	IF	Citations
55	Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry. Rheumatology International, 2022, 42, 2019-2026.	1.8	4
56	Management of contemporary early undifferentiated arthritis: data on EULAR's recommendation on the risk of persistent disease. Annals of the Rheumatic Diseases, 2022, 81, 740-741.	6.5	6
57	IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross-Sectional Study Encompassing ~1,500 Samples. Arthritis and Rheumatology, 2022, 74, 1147-1158.	4.5	55
58	MRI-Based Classification of Neuropsychiatric Systemic Lupus Erythematosus Patients With Self-Supervised Contrastive Learning. Frontiers in Neuroscience, 2022, 16, .	2.0	23
59	Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology, 2022, 61, 4024-4034.	1.4	18
60	In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. Rheumatology, 2022, 62, 407-416.	1.4	17
61	Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Science Advances, 2022, 8, .	8.1	77
62	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 937-943.	6.5	20
63	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. RMD Open, 2022, 8, e002079.	2.7	14
64	Rheumatic?—A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Pilot Validation Study. Frontiers in Medicine, 2022, 9, .	1.6	15
65	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. Clinical and Experimental Rheumatology, 2022, 40, 66-70.	3.1	5
66	ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation. Rheumatology, 2022, 62, 124-134.	1.4	10
67	Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nature Genetics, 2022, 54, 1640-1651.	14.1	353
68	Glycobiology of rheumatic diseases. Nature Reviews Rheumatology, 2022, 19, 28-43.	17.6	97
69	Tract-based white matter hyperintensity patterns in patients with systemic lupus erythematosus using an unsupervised machine learning approach. Scientific Reports, 2022, 12, .	2.7	13
70	Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD Open, 2022, 8, e002683.	2.7	4
71	Shrinking Lung Syndrome. Journal of Clinical Rheumatology, 2021, 27, S525-S529.	0.7	8
72	Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 402-409.	1.3	10

#	Article	IF	Citations
73	Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature. Arthritis Care and Research, 2021, 73, 722-731.	2.2	6
74	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 921-930.	4.5	29
75	Quantitative susceptibility mapping in the thalamus and basal ganglia of systemic lupus erythematosus patients with neuropsychiatric complaints. NeuroImage: Clinical, 2021, 30, 102637.	2.2	8
76	Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology, 2021, , .	1.4	54
77	Earlier chronotype in patients with rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 2185-2192.	1.3	15
78	Phenotype and treatment of elderly onset compared with younger onset rheumatoid arthritis patients in international daily practice. Rheumatology, 2021, 60, 4801-4810.	1.4	19
79	Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. Lupus, 2021, 30, 1124-1132.	1.0	36
80	Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis. PLoS ONE, 2021, 16, e0247847.	1.5	9
81	Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI. European Radiology, 2021, 31, 8208-8217.	3.0	23
82	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 2338-2347.	4.5	31
83	Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. Annals of the Rheumatic Diseases, 2021, 80, 1124-1129.	6.5	15
84	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. RMD Open, 2021, 7, e001524.	2.7	9
85	Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review. Arthritis Research and Therapy, 2021, 23, .	2.9	25
86	White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms. RMD Open, 2021, 7, e001650.	2.7	16
87	A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with Löfgren's Syndrome and Alters Receptor Expression as well as Functional Response. Cells, 2021, 10, 1967.	3.3	5
88	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. Arthritis Research and Therapy, 2021, 23, .	2.9	22
89	Disease progression in systemic sclerosis. Rheumatology, 2021, 60, 1565-1567.	1.4	14
90	Dissociation in SLE: A part of lupus fog?. Lupus, 2021, 30, 2151-2156.	1.0	2

#	Article	IF	Citations
91	Longitudinal changes in cerebral white matter microstructure in newly diagnosed systemic lupus erythematosus patients. Rheumatology, 2021, 60, 2678-2687.	1.4	18
92	Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications. Arthritis Research and Therapy, 2021, 23, .	2.9	16
93	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 140-148.	1.9	28
94	An overview of autoantibodies in rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102392.	3.8	355
95	Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. Science Translational Medicine, 2020, 12, .	8.7	104
96	Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. Lupus, 2020, 29, 1892-1901.	1.0	28
97	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open, 2020, 6, e001370.	2.7	38
98	Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. PLoS Medicine, 2020, 17, e1003296.	4.6	91
99	Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?. RMD Open, 2020, 6, e001242.	2.7	23
100	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1084-1089.	6.5	52
101	Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. Science Translational Medicine, 2020, 12, .	8.7	55
102	Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry. RMD Open, 2020, 6, e001203.	2.7	9
103	P1473 Detection of cardiac sources of cerebrovascular events in patient with systemic lupus erythematosus with neuropsychiatric manifestations. European Heart Journal Cardiovascular Imaging, 2020, 21, .	1.1	0
104	Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1897-1904.	4.5	42
105	Left Ventricular Systolic Function in Patients with Systemic Lupus Erythematosus and Its Association with Cardiovascular Events. Journal of the American Society of Echocardiography, 2020, 33, 1116-1122.	2.5	33
106	Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Annals of the Rheumatic Diseases, 2020, 79, 472-480.	6.5	124
107	Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study. Musculoskeletal Care, 2020, 18, 177-186.	1.0	7
108	On using machine learning algorithms to define clinically meaningful patient subgroups. Annals of the Rheumatic Diseases, 2020, 79, e154.	6.5	5

#	Article	IF	Citations
109	Disruptive innovation in rheumatology: new networks of global public–private partnerships are needed to take advantage of scientific progress. Annals of the Rheumatic Diseases, 2020, 79, 553-555.	6.5	2
110	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. Arthritis Research and Therapy, 2020, 22, .	2.9	4
111	Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatology and Therapy, 2020, 8, 41-61.	1.7	54
112	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	4.6	58
113	One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 181-194.	3.1	37
114	Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening. Journal of Rheumatology, 2019, 46, 1244.1-1245.	1.3	0
115	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. Rheumatology, 2019, 58, 730-732.	1.4	15
116	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Research and Therapy, 2019, 21, .	2.9	53
117	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. Annals of the Rheumatic Diseases, 2019, 78, 908-916.	6.5	48
118	N-Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1626-1633.	4.5	116
119	Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. Arthritis Research and Therapy, 2019, 21, .	2.9	8
120	ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Research and Therapy, 2019, 21, .	2.9	25
121	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 2019, 5, e000840.	2.7	9
122	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	6.5	34
123	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. Journal of Rheumatology, 2019, 46, 405-415.	1.3	27
124	Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients. Scientific Reports, 2019, 9, .	2.7	43
125	Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry. RMD Open, 2019, 5, e000969.	2.7	6
126	Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Research and Therapy, 2019, 21, .	2.9	27

#	Article	IF	Citations
127	How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions. Pain Reports, 2019, 4, e699.	1.9	71
128	Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology, 2019, 58, 149-153.	1.4	18
129	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2019, 7, 6-11.	3.1	164
130	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Seminars in Arthritis and Rheumatism, 2019, 48, 967-975.	1.9	55
131	Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, e1-e2.	6.5	33
132	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. Scandinavian Journal of Rheumatology, 2018, 47, 360-363.	0.6	8
133	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open, 2018, 4, e000564.	2.7	43
134	Dosing down with biologic therapies: a systematic review and clinicians' perspective. Rheumatology, 2018, 57, 589-589.	1.4	5
135	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2018, 47, 270-275.	0.6	3
136	The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nature Reviews Rheumatology, 2018, 14, 157-169.	17.6	107
137	Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Research and Therapy, 2018, 20, .	2.9	52
138	Is optimising gout treatment the key to closing the mortality gap in gout patients?. Annals of the Rheumatic Diseases, 2018, 77, e2.	6.5	1
139	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Annals of the Rheumatic Diseases, 2018, 77, 1087-1088.	6.5	16
140	Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Annals of the Rheumatic Diseases, 2018, 77, 111-118.	6.5	72
141	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 1757-1764.	6.5	162
142	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology, 2018, 57, 1707-1720.	1.4	34
143	Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nature Genetics, 2018, 50, 1366-1374.	14.1	144
144	Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1721-1731.	4.5	115

#	Article	IF	Citations
145	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. Rheumatology, 2018, 57, 1583-1591.	1.4	13
146	MR signal intensity: staying on the bright side in MR image interpretation. RMD Open, 2018, 4, e000728.	2.7	83
147	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Annals of the Rheumatic Diseases, 2018, 77, 1836-1838.	6.5	19
148	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology, 2018, 57, 1423-1431.	1.4	35
149	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, .	2.9	24
150	Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. RMD Open, 2018, 4, e000649.	2.7	9
151	Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans. Molecular and Cellular Proteomics, 2017, 16, 278-287.	3.2	102
152	The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Annals of the Rheumatic Diseases, 2017, 76, 112-118.	6.5	82
153	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Annals of the Rheumatic Diseases, 2017, 76, 716-720.	6.5	45
154	Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis and Rheumatology, 2017, 69, 926-931.	4.5	52
155	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Annals of the Rheumatic Diseases, 2017, 76, 1184-1190.	6.5	95
156	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	6.5	3,522
157	Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans. Osteoarthritis and Cartilage, 2017, 25, 1150-1160.	3.0	77
158	Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort. Lupus, 2017, 26, 543-551.	1.0	27
159	Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life. Lupus, 2017, 26, 1252-1259.	1.0	38
160	Dosing down with biologic therapies: a systematic review and clinicians' perspective. Rheumatology, 2017, 56, 1847-1856.	1.4	70
161	Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus. Rheumatology, 2017, 56, 1407-1416.	1.4	23
162	Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. Rheumatology, 2017, 56, 1367-1377.	1.4	36

#	Article	IF	Citations
163	Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. International Journal of Cardiology, 2017, 240, 20-24.	1.6	14
164	Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases, 2017, 76, 1449-1457.	6.5	35
165	The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 437-446.	5.7	307
166	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Research and Therapy, 2017, 19, .	2.9	37
167	Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1751-1754.	6.5	75
168	Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 249-262.	2.0	134
169	Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort. Journal of Rheumatology, 2017, 44, 1659-1666.	1.3	58
170	Rituximab in early systemic sclerosis. RMD Open, 2017, 3, e000384.	2.7	63
171	Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2017, 43, 347-361.	0.8	14
172	Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1915-1923.	6.5	56
173	Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents. RMD Open, 2017, 3, e000568.	2.7	19
174	Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study. RMD Open, 2017, 3, e000419.	2.7	29
175	Pathway Analysis to Identify Genetic Variants Associated with Efficacy of Adalimumab in Rheumatoid Arthritis. Pharmacogenomics, 2017, 18, 945-953.	0.7	7
176	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Rheumatology, 2017, 56, 1721-1728.	1.4	8
177	Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clinical Rheumatology, 2017, 36, 1487-1492.	1.3	40
178	Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology, 2017, 56, 77-86.	1.4	133
179	Brief Report: The Role of Rare Protein-Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 735-741.	4.5	8
180	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. Arthritis Care and Research, 2017, 69, 717-723.	2.2	24

#	Article	IF	Citations
181	229. CLINICAL RESPONSES OF SARILUMAB BASED ON RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56, .	1.4	1
182	Using a reference when defining an abnormal MRI reduces false-positive MRI results—a longitudinal study in two cohorts at risk for rheumatoid arthritis. Rheumatology, 2017, 56, 1700-1706.	1.4	51
183	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Research and Therapy, 2017, 19, .	2.9	28
184	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, .	2.9	3
185	P5410Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis. European Heart Journal, 2017, 38, .	2.6	0
186	Preventing progression from arthralgia to arthritis: targeting the right patients. Nature Reviews Rheumatology, 2017, 14, 32-41.	17.6	114
187	The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. Arthritis and Rheumatology, 2016, 68, 1080-1088.	4.5	59
188	The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA: Table 1. Rheumatology, 2016, 55, 199-209.	1.4	132
189	079 Abatacept Plus Methotrexate can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis. Rheumatology, 2016, , .	1.4	0
190	The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Current Opinion in Rheumatology, 2016, 28, 275-281.	2.4	21
191	Human mast cells costimulate T cells through a CD28-independent interaction. European Journal of Immunology, 2016, 46, 1132-1141.	2.2	11
192	Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis. RMD Open, 2016, 2, e000159.	2.7	53
193	Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. RMD Open, 2016, 2, e000186.	2.7	13
194	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, .	2.9	58
195	Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies. Annals of the Rheumatic Diseases, 2016, 75, 2201-2207.	6.5	31
196	TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Science and Medicine, 2016, 3, e000169.	1.6	27
197	Aesthetic dissatisfaction in patients with hand osteoarthritis and its impact on daily life. Scandinavian Journal of Rheumatology, 2016, 45, 219-223.	0.6	13
198	Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open, 2016, 2, e000172.	2.7	15

#	Article	IF	Citations
199	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	2.7	46
200	Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons. Arthritis Research and Therapy, 2016, 18, .	2.9	22
201	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1501-1505.	6.5	19
202	P28 TAC-TIC USE OF TACROLIMUS-BASED REGIMENS IN LUPUS NEPHRITIS. Kidney International Reports, 2016, 1, S13-S14.	2.0	0
203	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open, 2016, 2, e000262.	2.7	30
204	Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. Annals of Internal Medicine, 2016, 164, 523-531.	7.3	114
205	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Annals of the Rheumatic Diseases, 2016, 75, 952-957.	6.5	317
206	The increased ability to present citrullinated peptides is not unique to HLA-SE molecules: arginine-to-citrulline conversion also enhances peptide affinity for HLA-DQ molecules. Arthritis Research and Therapy, 2016, 18, .	2.9	29
207	Repeated FcεRI triggering reveals modified mast cell function related to chronic allergic responses in tissue. Journal of Allergy and Clinical Immunology, 2016, 138, 869-880.	4.4	23
208	Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis. Rheumatology, 2016, 55, 1386-1393.	1.4	27
209	The production and secretion of complement component C1q by human mast cells. Molecular Immunology, 2016, 78, 164-170.	2.0	43
210	Older age is associated with more MRI-detected inflammation in hand and foot joints. Rheumatology, 2016, 55, 2212-2219.	1.4	24
211	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Research and Therapy, 2016, 18, .	2.9	64
212	Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. Arthritis Research and Therapy, 2016, 18, .	2.9	31
213	Magnetic resonance imaging-detected inflammation is associated with functional disability in early arthritis—results of a cross-sectional study. Rheumatology, 2016, 55, 2167-2175.	1.4	19
214	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, .	10.8	78
215	Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial. RMD Open, 2016, 2, e000143.	2.7	13
216	Age affects joint space narrowing in patients with early active rheumatoid arthritis. RMD Open, 2016, 2, e000338.	2.7	3

#	Article	IF	Citations
217	Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation. Arthritis Care and Research, 2016, 68, 446-453.	2.2	22
218	Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Research and Therapy, 2016, 18, .	2.9	45
219	Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus, 2016, 25, 878-888.	1.0	44
220	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. BMC Musculoskeletal Disorders, 2016, 17, .	1.5	2
221	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 578-585.	6.5	193
222	Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Annals of the Rheumatic Diseases, 2016, 75, 867-873.	6.5	77
223	Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Annals of the Rheumatic Diseases, 2016, 75, 1924-1932.	6.5	67
224	Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology, 2016, 55, 357-366.	1.4	34
225	Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. Brain, 2016, 139, 1447-1457.	5.9	74
226	Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, e14.	6.5	6
227	Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. Annals of the Rheumatic Diseases, 2016, 75, 1891-1898.	6.5	15
228	Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1824-1830.	6.5	168
229	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2016, 75, 1308-1314.	6.5	104
230	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1170-1176.	6.5	97
231	Rheumatologists' adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission. Clinical Rheumatology, 2016, 36, 317-326.	1.3	12
232	087 On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. Rheumatology, 2016, , .	1.4	1
233	A prediction model for progressive disease in systemic sclerosis. RMD Open, 2015, 1, e000113.	2.7	9
234	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Research and Therapy, 2015, 17, .	2.9	108

#	Article	IF	Citations
235	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, .	2.9	22
236	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Research and Therapy, 2015, 17, .	2.9	81
237	Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. Arthritis Research and Therapy, 2015, 17, .	2.9	22
238	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, .	2.9	81
239	Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis' – authors' reply. Arthritis Research and Therapy, 2015, 17, .	2.9	0
240	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Research and Therapy, 2015, 17, .	2.9	23
241	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 2015, 17, .	2.9	18
242	Ability of Interleukin-33– and Immune Complex–Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses. Arthritis and Rheumatology, 2015, 67, 2343-2353.	4.5	55
243	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 409-423.	0.9	91
244	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis and Rheumatology, 2015, 67, 1424-1437.	4.5	246
245	Concordance between inflammation at physical examination and on MRI in patients with early arthritis. Annals of the Rheumatic Diseases, 2015, 74, 506-512.	6.5	54
246	Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 883-889.	6.5	22
247	Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort: Table 3. Rheumatology, 2015, 54, 1336-1336.	1.4	8
248	IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, .	2.9	24
249	Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Annals of the Rheumatic Diseases, 2015, 74, 1225-1232.	6.5	114
250	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. Immunobiology, 2015, 220, 422-427.	0.9	17
251	Continued Participation in a Ten-Year Tight Control Treat-to-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing their Best?. Arthritis Care and Research, 2015, 67, 739-745.	2.2	10
252	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases, 2015, 74, 19-26.	6.5	235

#	Article	IF	Citations
253	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. Journal of Rheumatology, 2015, 42, 572-579.	1.3	130
254	Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?. Journal of Internal Medicine, 2015, 277, 178-187.	4.0	17
255	A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, .	2.9	149
256	The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Annals of the Rheumatic Diseases, 2015, 74, 1842-1847.	6.5	199
257	Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment. Rheumatology, 2015, 54, 1380-1384.	1.4	13
258	Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?. European Radiology, 2015, 25, 1520-1527.	3.0	47
259	Mortality in osteoarthritis patients. Scandinavian Journal of Rheumatology, 2015, 44, 70-73.	0.6	33
260	Immunogenetics of rheumatoid arthritis: Understanding functional implications. Journal of Autoimmunity, 2015, 64, 74-81.	3.8	73
261	Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study. Journal of Rheumatology, 2015, 42, 1383-1391.	1.3	27
262	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. Rheumatology, 2015, 54, 1930-1932.	1.4	25
263	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. Journal of Autoimmunity, 2015, 62, 39-44.	3.8	42
264	A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. NeuroImage: Clinical, 2015, 8, 337-344.	2.2	58
265	Association of Valine and Leucine at HLA–DRB1 Position 11 With Radiographic Progression in Rheumatoid Arthritis, Independent of the Shared Epitope Alleles but Not Independent of Anti–Citrullinated Protein Antibodies. Arthritis and Rheumatology, 2015, 67, 877-886.	4.5	20
266	The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1886-1889.	6.5	29
267	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. Annals of the Rheumatic Diseases, 2015, 74, 949-950.	6.5	20
268	FcGRGenetic Polymorphisms and the Response to Adalimumab in Patients with Rheumatoid Arthritis. Pharmacogenomics, 2015, 16, 373-381.	0.7	32
269	IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology, 2015, 54, 728-735.	1.4	54
270	Evaluation of Magnetic Resonance Imaging–Detected Tenosynovitis in the Hand and Wrist in Early Arthritis. Arthritis and Rheumatology, 2015, 67, 869-876.	4.5	69

#	Article	IF	Citations
271	Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open, 2015, 1, e000041.	2.7	73
272	Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. Rheumatology, 2015, , kev342.	1.4	4
273	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nature Genetics, 2015, 47, 1085-1090.	14.1	195
274	Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Annals of the Rheumatic Diseases, 2015, 74, 35-43.	6.5	97
275	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology, 2015, 44, 1706-1721.	2.8	58
276	Abatacept decreases disease activity in the absence of CD4+ T cells in a collagen-induced arthritis model. Arthritis Research and Therapy, 2015, 17, .	2.9	23
277	Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2015, 54, 1630-1639.	1.4	30
278	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 234-241.	6.5	269
279	Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors. Annals of the Rheumatic Diseases, 2015, 74, 876-882.	6.5	11
280	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.5	40
281	87. Comparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis. Rheumatology, 2014, 53, i88-i89.	1.4	1
282	Differential methylation within the major histocompatibility complex region in rheumatoid arthritis: a replication study. Rheumatology, 2014, 53, 2317-2318.	1.4	17
283	Autoimmunity: Break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Immunology Letters, 2014, 162, 150-162.	1.6	5
284	Are Baseline High Molecular Weight Adiponectin Levels Associated with Radiographic Progression in Rheumatoid Arthritis and Osteoarthritis?. Journal of Rheumatology, 2014, 41, 853-857.	1.3	13
285	MRI-detected subclinical joint inflammation is associated with radiographic progression. Annals of the Rheumatic Diseases, 2014, 73, 2034-2037.	6.5	35
286	Does a Genetic Variant in FOXO3A Predict a Milder Course of Rheumatoid Arthritis?. Arthritis and Rheumatology, 2014, 66, 1678-1681.	4.5	9
287	Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology, 2014, 53, 2122-2124.	1.4	66
288	Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Annals of the Rheumatic Diseases, 2014, 73, 396-400.	6.5	59

#	Article	IF	Citations
289	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, .	2.9	5
290	Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study. Journal of Rheumatology, 2014, 41, 1630-1637.	1.3	25
291	Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. Rheumatology, 2014, 53, 771-771.	1.4	0
292	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmunity Reviews, 2014, 13, 225-230.	5.3	123
293	What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Annals of the Rheumatic Diseases, 2014, 73, 861-870.	6.5	301
294	The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Seminars in Immunopathology, 2014, 36, 313-325.	5.7	26
295	Health care in systemic lupus erythematosus (SLE): the patient's perspective. Clinical Rheumatology, 2014, 33, 1279-1287.	1.3	12
296	Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus, 2014, 23, 31-38.	1.0	107
297	A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study. Journal of Rheumatology, 2014, 41, 2114-2119.	1.3	42
298	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 270-276.	6.5	45
299	Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Annals of the Rheumatic Diseases, 2014, 73, 1626-1634.	6.5	206
300	HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis. Annals of the Rheumatic Diseases, 2014, 73, 633-634.	6.5	0
301	Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee. Annals of the Rheumatic Diseases, 2014, 73, 567-572.	6.5	30
302	Long-term outcome of Rheumatoid Arthritis defined according to the 2010-classification criteria. Annals of the Rheumatic Diseases, 2014, 73, 428-432.	6.5	32
303	Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?. European Radiology, 2014, 24, 2614-2622.	3.0	37
304	Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in Löfgren's syndrome. Cytokine, 2014, 69, 272-276.	2.0	12
305	Is HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort. Journal of Rheumatology, 2014, 41, 1948-1951.	1.3	1
306	IgE and IL-33–mediated triggering of human basophils inhibits TLR4–induced monocyte activation. European Journal of Immunology, 2014, 44, 3045-3055.	2.2	36

#	Article	IF	Citations
307	Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice—a translational model for atherosclerosis. Annals of the Rheumatic Diseases, 2014, 73, 921-927.	6.5	86
308	Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody–negative arthralgia patients at risk for rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, .	2.9	36
309	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, .	2.9	23
310	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. American Journal of Human Genetics, 2014, 94, 522-532.	4.0	171
311	Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells. European Journal of Immunology, 2014, 44, 386-396.	2.2	66
312	Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK. Pharmacoeconomics, 2014, 32, 775-787.	2.4	28
313	Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 2038-2046.	6.5	44
314	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 780-783.	6.5	212
315	Degree of synovitis on MRI by comprehensive whole knee semi-quantitative scoring method correlates with histologic and macroscopic features of synovial tissue inflammation in knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 1606-1613.	3.0	62
316	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, 1761-1768.	6.5	137
317	HLA and rheumatoid arthritis: How do they connect?. Annals of Medicine, 2014, 46, 304-310.	2.5	29
318	Comparative Efficacy Of Novel Dmards As Monotherapy And In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Dmards – A Network Meta-Analysis. Value in Health, 2014, 17, A41-A42.	1.0	0
319	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. PLoS ONE, 2014, 9, e102163.	1.5	42
320	The relationship between disease activity and depressivesymptoms severity and optimism—results from the IMPROVED study. Clinical Rheumatology, 2013, 32, 1751-1757.	1.3	12
321	An innovative care model coordinated by a physical therapist and nurse practitioner for osteoarthritis of the hip and knee in specialist care: a prospective study. Rheumatology International, 2013, 33, 1821-1828.	1.8	17
322	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1259-1263.	6.5	75
323	Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. Annals of the Rheumatic Diseases, 2013, 72, ii76-ii79.	6.5	73
324	Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence. Rheumatology, 2013, 52, 1220-1224.	1.4	94

#	Article	IF	Citations
325	Demyelinating disease in SLE: Is it multiple sclerosis or lupus?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 405-424.	3.3	54
326	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1375-1381.	6.5	100
327	DX5 +CD4 +T cells modulate CD4 +T-cell response via inhibition of IL-12 production by DCs. European Journal of Immunology, 2013, 43, 439-446.	2.2	4
328	In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Annals of the Rheumatic Diseases, 2013, 72, 930-934.	6.5	74
329	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1897-1904.	6.5	123
330	Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, 974-978.	6.5	39
331	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. Annals of the Rheumatic Diseases, 2013, 72, 148-150.	6.5	80
332	Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus, 2013, 22, 171-179.	1.0	33
333	Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis Patients. Arthritis Care and Research, 2013, 65, 1235-1242.	2.2	84
334	Association study of candidate genes for the progression of hand osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, 565-569.	3.0	27
335	Autoimmunity in rheumatoid arthritis: different antigens—common principles. Annals of the Rheumatic Diseases, 2013, 72, ii132-ii136.	6.5	47
336	Personalized medicine: predicting responses to therapy in patients with RA. Current Opinion in Pharmacology, 2013, 13, 463-469.	2.8	30
337	MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1540-1544.	6.5	50
338	Drug therapy in undifferentiated arthritis: a systematic literature review. Annals of the Rheumatic Diseases, 2013, 72, 1436-1444.	6.5	37
339	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Annals of the Rheumatic Diseases, 2013, 72, 1646-1653.	6.5	141
340	'Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA'. Annals of the Rheumatic Diseases, 2013, 72, 870-874.	6.5	26
341	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 769-775.	6.5	83
342	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Annals of the Rheumatic Diseases, 2013, 72, 1059-1063.	6.5	28

#	Article	IF	Citations
343	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. Annals of the Rheumatic Diseases, 2013, 72, 1335-1341.	6.5	45
344	Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 307-308.	6.5	14
345	Prediction of Disease Outcome in Early Arthritis. Aktuelle Rheumatologie, 2013, 38, 30-36.	0.0	0
346	Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 624-629.	1.3	17
347	Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 182-189.	0.6	29
348	Autonomous online health assessment questionnaire registry in daily clinical practice. Rheumatology, 2013, 52, 883-887.	1.4	15
349	Pathogenic relevance of anti-citrullinated vimentin antibodies: Comment on the article by Montes et al. Arthritis and Rheumatism, 2013, 65, 541-542.	6.1	0
350	Review: The Preclinical Phase of Rheumatoid Arthritis: What Is Acknowledged and What Needs to be Assessed?. Arthritis and Rheumatism, 2013, 65, 2219-2232.	6.1	54
351	Brief Report: Anti–Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 911-915.	6.1	182
352	Patients with early arthritis consume less alcohol than controls, regardless of the type of arthritis. Rheumatology, 2013, 52, 1701-1707.	1.4	16
353	Metabolic Profiling Reveals Differences in Concentrations of Oxylipins and Fatty Acids Secreted by the Infrapatellar Fat Pad of Donors With End-Stage Osteoarthritis and Normal Donors. Arthritis and Rheumatism, 2013, 65, 2606-2614.	6.1	55
354	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	2.2	160
355	An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology, 2013, 52, 839-846.	1.4	65
356	Allele-Dose Association of the C5orf30 rs26232 Variant With Joint Damage in Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 2555-2561.	6.1	26
357	Evaluating joint destruction in rheumatoid arthritis: is it necessary to radiograph both hands and feet?. Annals of the Rheumatic Diseases, 2013, 72, 345-349.	6.5	26
358	Serum Pyridinoline Levels and Prediction of Severity of Joint Destruction in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1303-1306.	1.3	18
359	Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology, 2013, 52, 1492-1499.	1.4	172
360	Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. Rheumatology, 2013, 52, 1265-1270.	1.4	30

#	Article	IF	Citations
361	Dr. Zirkzee, et al reply. Journal of Rheumatology, 2013, 40, 204.2-204.	1.3	0
362	Risk Factors for Progression in Hand Osteoarthritis: A Systematic Review. Arthritis Care and Research, 2013, 65, 552-562.	2.2	31
363	Communication between human mast cells and CD4+T cells through antigen-dependent interactions. European Journal of Immunology, 2013, 43, 1758-1768.	2.2	59
364	Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Annals of the Rheumatic Diseases, 2013, 72, 43-50.	6.5	273
365	Platelets and autoimmunity. European Journal of Clinical Investigation, 2013, 43, 746-757.	2.2	109
366	Adipocyte-derived lipids modulate CD4+ T-cell function. European Journal of Immunology, 2013, 43, 1578-1587.	2.2	82
367	Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. Annals of the Rheumatic Diseases, 2013, 72, 1295-1301.	6.5	42
368	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nature Genetics, 2013, 45, 468-469.	14.1	24
369	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. Annals of the Rheumatic Diseases, 2013, 72, 1302-1307.	6.5	19
370	Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. Arthritis Research and Therapy, 2013, 15, .	2.9	22
371	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2013, 506, 376-381.	30.7	2,345
372	Health-care utilization in Dutch systemic sclerosis patients. Clinical Rheumatology, 2013, 33, 825-832.	1.3	13
373	Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. Clinical Rheumatology, 2013, 33, 461-466.	1.3	16
374	Profiling the Secretion of Soluble Mediators by End Stage Osteoarthritis Synovial Tissue Explants Reveals a Reduced Responsiveness to an Inflammatory Trigger. PLoS ONE, 2013, 8, e62634.	1.5	5
375	Cytokine-Suppressive Anti-Inflammatory Drugs. BioDrugs, 2012, 6, 395-404.	0.1	1
376	Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Annals of the Rheumatic Diseases, 2012, 71, 707-709.	6.5	68
377	Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 238-241.	6.5	50
378	Novel genetic association of the VTCN1 region with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 567-571.	6.5	13

#	Article	IF	Citations
379	Diagnostic value of performing chest x-rays in patients presenting with recent-onset arthritis. Annals of the Rheumatic Diseases, 2012, 71, 627-628.	6.5	2
380	Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy. Journal of Rheumatology, 2012, 39, 2118-2126.	1.3	72
381	No impact of serum uric acid on the outcome of recent-onset arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1424-1425.	6.5	6
382	Loss of metacarpal bone density predicts RA development in recent-onset arthritis. Rheumatology, 2012, 51, 1037-1041.	1.4	39
383	Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up. Annals of the Rheumatic Diseases, 2012, 71, 1530-1533.	6.5	33
384	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Annals of the Rheumatic Diseases, 2012, 71, 268-274.	6.5	65
385	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	6.5	440
386	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Annals of the Rheumatic Diseases, 2012, 71, 1472-1477.	6.5	97
387	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1366-1369.	6.5	48
388	Does the season at symptom onset influence the long-term severity of radiographic joint destruction in rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2012, 71, 2055-2056.	6.5	9
389	Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints. Rheumatology, 2012, 51, 2262-2268.	1.4	22
390	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.5	30
391	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	14.1	623
392	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 2012, 51, 2204-2214.	1.4	119
393	The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Annals of the Rheumatic Diseases, 2012, 71, 245-248.	6.5	90
394	The influence of ACPA status and characteristics on the course of RA. Nature Reviews Rheumatology, 2012, 8, 144-152.	17.6	208
395	Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2012, 41, 359-365.	0.6	22
396	Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. Scandinavian Journal of Rheumatology, 2012, 41, 15-19.	0.6	11

#	Article	IF	Citations
397	Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology, 2012, 51, 1120-1128.	1.4	40
398	The 2010 ACR/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2012, 71, 1596-1598.	6.5	27
399	Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskeletal Disorders, 2012, 13, .	1.5	34
400	Clinical Pharmacogenetic Model to Predict Response of MTX Monotherapy in Patients with Established Rheumatoid Arthritis After DMARD Failure. Pharmacogenomics, 2012, 13, 1087-1094.	0.7	35
401	Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis and Cartilage, 2012, 20, 1484-1499.	3.0	626
402	Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Research and Therapy, 2012, 14, .	2.9	50
403	Anticytomegalovirus seropositivity in rheumatoid arthritis is not associated with the presence of severe extraarticular complications: Comment on the article by Pierer et al. Arthritis and Rheumatism, 2012, 64, 2803-2804.	6.1	1
404	The additive value of magnetic resonance imaging for bone edema in predicting rheumatoid arthritis development in early undifferentiated arthritis: Comment on the article by Duer-Jensen et al. Arthritis and Rheumatism, 2012, 64, 321-322.	6.1	3
405	Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clinical Rheumatology, 2012, 32, 585-590.	1.3	29
406	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.5	15
407	Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Annals of the Rheumatic Diseases, 2011, 70, 60-67.	6.5	359
408	Predicting arthritis outcomes–what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology, 2011, 50, 93-100.	1.4	269
409	Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 315-319.	6.5	147
410	The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 1039-1046.	6.5	168
411	A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 168-171.	6.5	21
412	Animal models for arthritis: innovative tools for prevention and treatment. Annals of the Rheumatic Diseases, 2011, 70, 1357-1362.	6.5	109
413	Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study. Arthritis Research and Therapy, 2011, 13, .	2.9	36
414	Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?. Arthritis Research and Therapy, 2011, 13, .	2.9	21

#	Article	IF	Citations
415	Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 1389-1394.	6.5	107
416	Treatment strategies in recent onset rheumatoid arthritis. Current Opinion in Rheumatology, 2011, 23, 241-244.	2.4	13
417	Drug-free remission: is it already possible?. Current Opinion in Rheumatology, 2011, 23, 266-272.	2.4	24
418	Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis. European Journal of Human Genetics, 2011, 19, 908-914.	2.1	17
419	Body mass index and alignment and their interaction as risk factors for progression of knees with radiographic signs of osteoarthritis. Osteoarthritis and Cartilage, 2011, 19, 1117-1122.	3.0	50
420	Validity of joint space width measurements in hand osteoarthritis. Osteoarthritis and Cartilage, 2011, 19, 1349-1355.	3.0	20
421	Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics, 2011, 63, 459-466.	1.1	152
422	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. Arthritis Research and Therapy, 2011, 13, .	2.9	20
423	Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: Bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care and Research, 2011, 63, 1691-1699.	2.2	26
424	Classification of rheumatoid arthritis: Comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis and Rheumatism, 2011, 63, 37-42.	6.1	246
425	Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis and Rheumatism, 2011, 63, 1265-1273.	6.1	58
426	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis and Rheumatism, 2011, 63, 1823-1832.	6.1	60
427	Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis and Rheumatism, 2011, 63, 2567-2574.	6.1	106
428	Recommendations for publication of genetic association studies inArthritis & Rheumatism. Arthritis and Rheumatism, 2011, 63, 2839-2847.	6.1	19
429	Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: Relationship to functional capacity and ventricular arrhythmias. Arthritis and Rheumatism, 2011, 63, 3969-3978.	6.1	90
430	State of the art lecture: IP53. Inflammatory Arthritis: Prospects for Next Decade. Rheumatology, 2011, 50, iii11-iii11.	1.4	0
431	Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1465-1467.	6.5	23
432	PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 512-515.	6.5	60

#	Article	IF	Citations
433	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. Annals of the Rheumatic Diseases, 2011, 70, 1697-1698.	6.5	6
434	The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. Lupus, 2011, 20, 485-492.	1.0	16
435	Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1282-1284.	6.5	134
436	Osteophytes and joint space narrowing are independently associated with pain in finger joints in hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1835-1837.	6.5	72
437	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases, 2011, 70, 188-193.	6.5	129
438	Which elements of the criteria for RA are stable over time?. Rheumatology, 2011, 50, 248-249.	1.4	1
439	Simplified versions of the original disease activity score: validation in the BeSt trial. Annals of the Rheumatic Diseases, 2011, 70, 1471-1474.	6.5	6
440	Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1815-1821.	6.5	95
441	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17372-17377.	5.2	545
442	Health care usage in Dutch systemic lupus erythematosus patients. Lupus, 2011, 20, 1147-1154.	1.0	4
443	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1461-1464.	6.5	48
444	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Annals of the Rheumatic Diseases, 2011, 70, 373-379.	6.5	77
445	Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci. PLoS Genetics, 2011, 7, e1002004.	2.2	338
446	Determinants of absence of osteoarthritis in old age. Scandinavian Journal of Rheumatology, 2011, 40, 68-73.	0.6	40
447	Clinical and radiographic disease course of hand osteoarthritis and determinants of outcome after 6 years. Annals of the Rheumatic Diseases, 2011, 70, 68-73.	6.5	80
448	Systemic and local factors are involved in the evolution of erosions in hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 326-330.	6.5	28
449	A comparison between the simplified erosion and narrowing score and the Sharp–van der Heijde score: post hoc analysis from the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 714-716.	6.5	12
450	Limitations in daily activities are the major determinant of reduced health-related quality of life in patients with hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 334-336.	6.5	91

#	Article	IF	Citations
451	Association between Several Clinical and Radiological Determinants with Long-Term Clinical Progression and Good Prognosis of Lower Limb Osteoarthritis. PLoS ONE, 2011, 6, e25426.	1.5	24
452	Low innate production of interleukin-1β and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis and Cartilage, 2010, 18, 942-947.	3.0	73
453	Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis and Cartilage, 2010, 18, 1256-1262.	3.0	73
454	Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strains. Molecular Immunology, 2010, 48, 137-146.	2.0	8
455	DX5 + CD4 + T cells modulate cytokine production by CD4 + T cells towards IL-10 via the production of IL-4. European Journal of Immunology, 2010, 40, 2731-2740.	2.2	5
456	Validity of the disease activity score in undifferentiated arthritis. Arthritis Care and Research, 2010, 62, 1392-1398.	2.2	7
457	Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 117-125.	6.1	109
458	Protection against anti–citrullinated protein antibody–positive rheumatoid arthritis is predominantly associated with HLA–DRB1*1301: A meta-analysis of HLA–DRB1 associations with anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis in four European populations. Arthritis and Rheumatism, 2010, 62, 1236-1245.	6.1	145
459	Glycan profiling of anti–citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis and Rheumatism, 2010, 62, 1620-1629.	6.1	206
460	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti–tumor necrosis factor α therapy. Arthritis and Rheumatism, 2010, 62, 1849-1861.	6.1	122
461	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.1	275
462	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.1	8,367
463	Long-term impact of delay in assessment of patients with early arthritis. Arthritis and Rheumatism, 2010, 62, 3537-3546.	6.1	436
464	Tract-based spatial statistics on diffusion tensor imaging in systemic lupus erythematosus reveals localized involvement of white matter tracts. Arthritis and Rheumatism, 2010, 62, 3716-3721.	6.1	53
465	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	14.1	1,204
466	Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nature Genetics, 2010, 42, 814-816.	14.1	71
467	Genetic Variation of the Fc Gamma Receptor 3B Gene and Association with Rheumatoid Arthritis. PLoS ONE, 2010, 5, e13173.	1.5	25
468	Rheumatoid Arthritis. Annals of Internal Medicine, 2010, 153, ITC1-1.	7.3	43

#	Article	IF	Citations
469	Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1554-1561.	6.5	297
470	The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1730-1731.	6.5	4
471	Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. Annals of the Rheumatic Diseases, 2010, 69, 727-729.	6.5	42
472	How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis?. Rheumatology, 2010, 49, 1429-1435.	1.4	12
473	The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1110-1116.	6.5	73
474	Clinical burden of erosive hand osteoarthritis and its relationship to nodes. Annals of the Rheumatic Diseases, 2010, 69, 1784-1788.	6.5	71
475	Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability. Annals of the Rheumatic Diseases, 2010, 69, 585-587.	6.5	122
476	Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 2062-2066.	6.5	95
477	Genetic variants in the prediction of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1694-1696.	6.5	48
478	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	6.5	214
479	Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology, 2010, 49, 2210-2216.	1.4	58
480	Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1239-1242.	6.5	11
481	Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Annals of the Rheumatic Diseases, 2010, 69, 1342-1345.	6.5	59
482	Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 730-732.	6.5	62
483	Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 987-994.	6.5	132
484	Disease Activity Monitoring in Rheumatoid Arthritis in Daily Practice: Experiences with METEOR, a Free Online Tool. Journal of Rheumatology, 2010, 37, 2632-2633.	1.3	11
485	Antibodies toPorphyromonas gingivalisAre Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives. Journal of Rheumatology, 2010, 37, 1105-1112.	1.3	212
486	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Annals of the Rheumatic Diseases, 2010, 69, 696-699.	6.5	52

#	Article	IF	Citations
487	Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound. Annals of the Rheumatic Diseases, 2010, 69, 1367-1369.	6.5	120
488	Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 567-570.	6.5	33
489	The joint–gut axis in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2010, 4, 257-268.	0.9	126
490	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 964-975.	6.5	1,501
491	A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Annals of the Rheumatic Diseases, 2010, 69, 1333-1337.	6.5	189
492	Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Annals of the Rheumatic Diseases, 2010, 69, 2107-2113.	6.5	43
493	Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. Journal of Autoimmunity, 2010, 34, 390-399.	3.8	29
494	Rheumatoid arthritis. Lancet, The, 2010, 376, 1094-1108.	46.9	3,080
495	Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, .	2.9	32
496	TRAF1/C5polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies. Arthritis Research and Therapy, 2010, 12, .	2.9	17
497	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	6.5	3,886
498	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 807-812.	6.5	104
499	Recent advances in the management of rheumatoid arthritis. BMJ: British Medical Journal, 2010, 341, c6942-c6942.	0.1	56
500	Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Annals of the Rheumatic Diseases, 2009, 68, 1789-1790.	6.5	28
501	Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Annals of the Rheumatic Diseases, 2009, 68, 1011-1016.	6.5	84
502	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discovery Today, 2009, 14, 837-844.	5.0	9
503	The use of data from early arthritis clinics for clinical research. Best Practice and Research in Clinical Rheumatology, 2009, 23, 117-123.	3.3	10
504	DC-induced CD8+ T-cell response is inhibited by MHC class II-dependent DX5+CD4+ Treg. European Journal of Immunology, 2009, 39, 1765-1773.	2.2	9

#	Article	IF	Citations
505	Quantitative heritability of anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 916-923.	6.1	229
506	Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 1255-1260.	6.1	93
507	Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial. Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2009, 61, 974-978.	5.7	31
508	Anti–cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis and Rheumatism, 2009, 60, 1923-1931.	6.1	237
509	Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis and Rheumatism, 2009, 60, 2262-2271.	6.1	206
510	Illness perceptions in patients with osteoarthritis: Change over time and association with disability. Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2009, 61, 1054-1061.	5.7	107
511	Value of anti–modified citrullinated vimentin and third-generation anti–cyclic citrullinated peptide compared with second-generation anti–cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2232-2241.	6.1	145
512	Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2242-2247.	6.1	99
513	Brain involvement in rheumatoid arthritis: A magnetic resonance spectroscopy study. Arthritis and Rheumatism, 2009, 60, 3190-3195.	6.1	23
514	Variation in IL7R predisposes to sarcoid inflammation. Genes and Immunity, 2009, 10, 647-653.	1.9	42
515	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nature Genetics, 2009, 41, 1313-1318.	14.1	333
516	Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1775-1780.	6.5	46
517	The prognostic value of baseline erosions in undifferentiated arthritis. Arthritis Research and Therapy, 2009, 11, .	2.9	44
518	Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond. Annals of the Rheumatic Diseases, 2009, 68, 1371.	6.5	9
519	The BeSt story: on strategy trials in rheumatoid arthritis. Current Opinion in Rheumatology, 2009, 21, 291-298.	2.4	40
520	A european perspective on the 50th anniversary ofArthritis & Rheumatism. Arthritis and Rheumatism, 2008, 58, S136-S139.	6.1	0
521	Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 53-60.	6.1	136
522	Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor α. Arthritis and Rheumatism, 2008, 58, 1609-1618.	6.1	25

#	Article	IF	Citations
523	Reply. Arthritis and Rheumatism, 2008, 58, 1205-1205.	6.1	0
524	The inflammatory disease–associated variants in IL12B and IL23R are not associated with rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 1877-1881.	6.1	41
525	Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making. Arthritis and Rheumatism, 2008, 58, 2241-2247.	6.1	156
526	Marked differences in fine specificity and isotype usage of the anti–citrullinated protein antibody in health and disease. Arthritis and Rheumatism, 2008, 58, 3000-3008.	6.1	159
527	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nature Genetics, 2008, 40, 1216-1223.	14.1	505
528	Translating basic research into clinical rheumatology. Best Practice and Research in Clinical Rheumatology, 2008, 22, 299-310.	3.3	6
529	Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Research and Therapy, 2008, 10, 205.	2.9	137
530	Hyperpigmentation of the skin due to hydroxychloroquine. Scandinavian Journal of Rheumatology, 2008, 37, 158-158.	0.6	23
531	Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine, 2008, 26, 3528-3533.	2.0	64
532	Gene Therapy and Cement Injection for Restabilization of Loosened Hip Prostheses. Human Gene Therapy, 2008, 19, 83-96.	2.3	27
533	A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 769-774.	6.5	160
534	Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2008, 67, 128-130.	6.5	20
535	Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Annals of the Rheumatic Diseases, 2008, 67, 1194-1195.	6.5	37
536	Innate production of tumour necrosis factor Î± and interleukin 10 is associated with radiological progression of knee osteoarthritis. Annals of the Rheumatic Diseases, 2008, 67, 1165-1169.	6.5	53
537	Lupus and the central nervous system. Lupus, 2008, 17, 376-379.	1.0	19
538	Gene Therapy for the Treatment of Hip Prosthesis Loosening: Adverse Events in a Phase 1 Clinical Study. Human Gene Therapy, 2008, 19, 1029-1038.	2.3	7
539	Assistive devices: usage in patients with rheumatoid arthritis. Clinical Rheumatology, 2008, 28, 119-128.	1.3	52
540	A Large-Scale Rheumatoid Arthritis Genetic Study Identifies Association at Chromosome 9q33.2. PLoS Genetics, 2008, 4, e1000107.	2.2	78

#	Article	IF	Citations
541	Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients. Rheumatology, 2007, 46, 1092-1095.	1.4	44
542	A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis. PLoS Medicine, 2007, 4, e278.	4.6	240
543	The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Annals of the Rheumatic Diseases, 2007, 67, 713-716.	6.5	167
544	Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19966-19970.	5.2	61
545	Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis. American Journal of Human Genetics, 2007, 80, 867-875.	4.0	400
546	Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology, 2007, 47, 249-255.	1.4	303
547	Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis Research and Therapy, 2007, 9, .	2.9	11
548	Exploratory analysis of four polymorphisms in humanGGHandFPGSgenes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics, 2007, 8, 141-150.	0.7	60
549	The HLA–DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis and Rheumatism, 2007, 56, 425-432.	6.1	126
550	A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions. Arthritis and Rheumatism, 2007, 56, 433-440.	6.1	341
551	Reply. Arthritis and Rheumatism, 2007, 56, 694-695.	6.1	1
552	Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 2007, 56, 1424-1432.	6.1	385
553	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1765-1775.	6.1	239
554	Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1728-1735.	6.1	45
555	Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: Identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis and Rheumatism, 2007, 56, 2492-2502.	6.1	166
556	Association of smoking with the constitution of the anti–cyclic citrullinated peptide response in the absence of HLA–DRB1 shared epitope alleles. Arthritis and Rheumatism, 2007, 56, 2913-2918.	6.1	38
557	Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis and Rheumatism, 2007, 56, 3909-3918.	6.1	160
558	Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells. European Journal of Immunology, 2007, 37, 129-138.	2.2	974

#	Article	IF	Citations
559	Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: Short-term results. Joint Bone Spine, 2007, 74, 48-51.	1.8	10
560	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discovery Today, 2007, 12, 125-131.	5.0	57
561	Title is missing!. Arthritis Research and Therapy, 2006, 8, R165.	2.9	89
562	Title is missing!. Arthritis Research and Therapy, 2006, 8, 216.	2.9	42
563	Title is missing!. Arthritis Research and Therapy, 2006, 8, R38.	2.9	45
564	Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. Molecular Immunology, 2006, 43, 2045-2050.	2.0	32
565	HLA and RA Revisited: Citrullinated Food for the SE Hypothesis, the DR6 Effect, and NIMA. Human Immunology, 2006, 67, 454-459.	0.5	16
566	Genetics and clinical characteristics to predict rheumatoid arthritis: where are we now and what are the future prospects?. Future Rheumatology, 2006, 1, 79-89.	0.2	3
567	Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo. Immunology, 2006, 119, 499-506.	3.0	62
568	Interleukin-10 promoter polymorphisms in male and female fertility and fecundity. Genes and Immunity, 2006, 7, 688-692.	1.9	9
569	Arthrographies au cours des prothèses de hanche descellées. Évaluation des possibilités thérapeutiques intra-articulaires. Revue Du Rhumatisme (Edition Francaise), 2006, 73, 1351-1357.	0.0	0
570	Genetic markers of treatment response in rheumatoid arthritis. Current Rheumatology Reports, 2006, 8, 369-377.	2.7	13
571	Arthrography in loosened hip prostheses. Assessment of possibilities for intra-articular therapy. Joint Bone Spine, 2006, 73, 684-690.	1.8	4
572	Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis and Rheumatism, 2006, 54, 253-263.	6.1	142
573	Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis and Rheumatism, 2006, 55, 157-159.	6.1	75
574	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis and Rheumatism, 2006, 54, 1087-1095.	6.1	199
575	The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1117-1121.	6.1	312
576	Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis and Rheumatism, 2006, 54, 2028-2030.	6.1	29

#	Article	IF	Citations
577	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2830-2839.	6.1	126
578	Reply. Arthritis and Rheumatism, 2006, 54, 3372-3373.	6.1	0
579	Isotype distribution of ANTI–CYCLIC citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis and Rheumatism, 2006, 54, 3799-3808.	6.1	196
580	Detection of change in CNS involvement in neuropsychiatric SLE: A magnetization transfer study. Journal of Magnetic Resonance Imaging, 2006, 24, 812-816.	2.6	35
581	The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population. Rheumatology, 2006, 46, 617-621.	1.4	34
582	Selective Involvement of the Amygdala in Systemic Lupus Erythematosus. PLoS Medicine, 2006, 3, e499.	4.6	60
583	How evidence-based are advertisements in journals regarding the subspecialty of rheumatology?. Rheumatology, 2006, 45, 1154-1157.	1.4	22
584	Tumor Necrosis Factor-α Genetic Predisposing Factors Can Influence Clinical Severity in Nephropathia Epidemica. Viral Immunology, 2006, 19, 558-564.	0.9	37
585	Understanding the genetic contribution to rheumatoid arthritis. Current Opinion in Rheumatology, 2005, 17, 299-304.	2.4	101
586	Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood, 2005, 105, 2991-2994.	3.6	12
587	Reply. Arthritis and Rheumatism, 2005, 52, 677-677.	6.1	3
588	Association of the risk of osteoarthritis with high innate production of interleukin-1β and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis and Rheumatism, 2005, 52, 1443-1450.	6.1	53
589	Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 1999-2002.	6.1	138
590	An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis and Rheumatism, 2005, 52, 2637-2644.	6.1	115
591	Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 3058-3062.	6.1	166
592	Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis and Rheumatism, 2005, 52, 3433-3438.	6.1	528
593	CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Human Genetics, 2005, 118, 58-66.	1.8	65
594	A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. British Journal of Rheumatology, 2005, 44, 111-119.	2.1	55

#	Article	IF	Citations
595	RUNX1 intronic SNP is not associated with rheumatoid arthritis susceptibility in Dutch Caucasians. Rheumatology, 2005, 44, 1196-1196.	1.4	3
596	Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. Nature Clinical Practice Rheumatology, 2005, 1, 2-3.	4.8	17
597	Bilateral hydropneumothoraces in a patient with pulmonary rheumatoid nodules during treatment with methotrexate. Annals of the Rheumatic Diseases, 2005, 64, 1661-1662.	6.5	4
598	Redefining the HLA and RA association: To be or not to be anti-CCP positive. Journal of Autoimmunity, 2005, 25, 21-25.	3.8	78
599	Elevated formation of pyridinoline cross-links by profibrotic cytokines is associated with enhanced lysyl hydroxylase 2b levels. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 95-102.	2.8	98
600	The type of collagen cross-link determines the reversibility of experimental skin fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 60-67.	2.8	139
601	IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine, 2005, 29, 215-228.	2.0	41
602	Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, .	2.9	433
603	Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Human Molecular Genetics, 2004, 13, 1755-1762.	2.1	252
604	Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17180-17185.	5.2	77
605	Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus. British Journal of Rheumatology, 2004, 43, 1402-1404.	2.1	38
606	Interleukin 10-2849AA genotype protects against pre-eclampsia. Genes and Immunity, 2004, 5, 313-314.	1.9	40
607	Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes and Immunity, 2004, 5, 592-595.	1.9	69
608	Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Experimental Gerontology, 2004, 39, 1407-1414.	2.9	108
609	Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 395-399.	6.1	70
610	Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis and Rheumatism, 2004, 50, 709-715.	6.1	579
611	Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip. Arthritis and Rheumatism, 2004, 50, 1179-1186.	6.1	101
612	Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 2113-2121.	6.1	338

#	Article	IF	Citations
613	Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis and Rheumatism, 2004, 50, 3354-3364.	6.1	63
614	Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biology, 2004, 23, 251-257.	3.4	203
615	Title is missing!. Quality of Life Research, 2003, 12, 635-644.	1.7	78
616	Interleukin−10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. Immunogenetics, 2003, 54, 896-899.	1.1	51
617	Evidence for non-random distribution of Fcγ receptor genotype combinations. Immunogenetics, 2003, 55, 240-246.	1.1	57
618	Genetics in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2003, 17, 703-716.	3.3	16
619	High innate production of interleukin-10 and tumor necrosis factor-α contributes to susceptibility for non-paraneoplastic Lambert–Eaton myasthenic syndrome. Journal of Neuroimmunology, 2003, 140, 194-197.	1.7	18
620	Analysis of allelic expression patterns of IL-2, IL-3, IL-4, and IL-13 in human CD4+ T cell clones. European Journal of Immunology, 2003, 33, 2142-2148.	2.2	8
621	Fibroblast-like synoviocytes from rheumatoid arthritis patients express less FLICE-inhibitory protein than fibroblast-like synoviocytes from trauma patients: Comment on the article by Schedel et al. Arthritis and Rheumatism, 2003, 48, 858-859.	6.1	3
622	Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3 CR1 and rheumatoid arthritis. Tissue Antigens, 2003, 62, 170-174.	0.6	14
623	Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clinical and Experimental Immunology, 2003, 134, 335-343.	2.3	58
624	Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes and Immunity, 2003, 4, 187-196.	1.9	323
625	Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. British Journal of Rheumatology, 2003, 42, 969-971.	2.1	12
626	Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis. Journal of Biological Chemistry, 2003, 278, 40967-40972.	1.3	383
627	Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology, 2002, 59, 549-555.	0.7	54
628	Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus, 2002, 11, 181-185.	1.0	47
629	Tumor Necrosis Factor-α +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respiratory Research, 2002, 3, .	2.8	63
630	Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Human Immunology, 2002, 63, 281-285.	0.5	49

#	Article	IF	Citations
631	Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 172-179.	1.7	116
632	Genetic drift as an explanation for the reduced incidence of rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 3107-3107.	6.1	21
633	The R-H polymorphism of FC? receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. Arthritis and Rheumatism, 2002, 46, 1125-1126.	6.1	22
634	Genetics in rheumatoid arthritis. Current Rheumatology Reports, 2002, 4, 195-200.	2.7	4
635	Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes and Immunity, 2002, 3, 25-29.	1.9	50
636	FUNCTIONAL ANALYSIS OF LINKER-SCAN MUTANTS SPANNING THE −376, −308, −244, AND −238 POLYMORPHIC SITES OF THE TNF-α PROMOTER. Cytokine, 2001, 14, 316-323.	2.0	117
637	Imaging modalities in central nervous system systemic lupus erythematosus. Current Opinion in Rheumatology, 2001, 13, 383-388.	2.4	48
638	The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis and Rheumatism, 2001, 44, 48-52.	6.1	36
639	Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis and Rheumatism, 2001, 44, 570-577.	6.1	41
640	Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 2001, 44, 1515-1524.	6.1	392
641	The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism, 2001, 44, 2525-2530.	6.1	188
642	Optimizing human fertility and survival. Nature Medicine, 2001, 7, 873-873.	22.6	83
643	Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes and Immunity, 2001, 2, 135-144.	1.9	86
644	Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF−308A in systemic lupus erythematosus. Genes and Immunity, 2001, 2, 373-380.	1.9	52
645	Relevance of Fcγ Receptor and Interleukin-10 Polymorphisms for Meningococcal Disease. Journal of Infectious Diseases, 2001, 184, 1548-1555.	2.2	104
646	Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Annals of Neurology, 2000, 48, 641-646.	4.6	47
647	CNS involvement in primary Sjögren's syndrome: a case with a clue for the pathogenesis. Journal of Neurology, 2000, 247, 63-64.	2.7	27
648	Reliability and sensitivity to change of various measures of hand function in relation to treatment of synovitis of the metacarpophalangeal joint in rheumatoid arthritis. Rheumatology, 2000, 39, 909-913.	1.4	14

#	Article	IF	Citations
649	Low soluble FcRIII receptor demonstrates reduced neutrophil reserves in preterm neonates. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2000, 83, 160F-160.	1.4	40
650	Neuropsychiatric systemic lupus erythematosus. Annals of the Rheumatic Diseases, 1999, 58, 658-659.	6.5	1
651	Feasibility of Adenovirus-Mediated Nonsurgical Synovectomy in Collagen-Induced Arthritis-Affected Rhesus Monkeys. Human Gene Therapy, 1999, 10, 1139-1149.	2.3	64
652	Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes and Immunity, 1999, 1, 91-96.	1.9	58
653	Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes and Immunity, 1999, 1, 151-155.	1.9	212
654	Polymorphism within the tumor necrosis factor α (TNF) promoter region in patients with ankylosing spondylitis. Human Immunology, 1999, 60, 140-144.	0.5	40
655	Determination of tumour necrosis factor-α and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. Journal of Immunological Methods, 1998, 218, 63-71.	1.0	132
656	An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics, 1998, 48, 394-401.	1.1	59
657	Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE). Clinical and Experimental Immunology, 1998, 111, 359-364.	2.3	29
658	Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet, The, 1998, 352, 1282-1283.	46.9	105
659	Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9465-9470.	5.2	463
660	Functional Analysis of a Human Tumor Necrosis Factor α (TNF-α) Promoter Polymorphism Related to Joint Damage in Rheumatoid Arthritis. Molecular Medicine, 1998, 4, 724-733.	4.3	98
661	The effect of pentoxifylline on human neutrophil migration: A possible role for cyclic nucleotides. Biochemical Pharmacology, 1997, 54, 475-480.	3.7	16
662	Genetic influence on cytokine production and fatal meningococcal disease. Lancet, The, 1997, 349, 170-173.	46.9	776
663	TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. Journal of Neuroimmunology, 1997, 72, 149-153.	1.7	219
664	Possibility and safety of gene transfer to inflamed synovial tissue after intra-articular administration. Immunology Letters, 1997, 56, 38.	1.6	0
665	Clinical value of soluble IgG Fc receptor type III (sFcγRIII) in plasma from patients with neutropenia. Immunology Letters, 1997, 56, 403.	1.6	0
666	Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Human Genetics, 1996, 97, 813-818.	1.8	16

#	Article	IF	Citations
667	Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. Kidney International, 1996, 49, 403-412.	4.2	41
668	Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Human Genetics, 1995, 96, .	1.8	36
669	Changes in Plasma FcRIII Demonstrate Increasing Receptor Production during Late Pregnancy and after Preterm Birth. Pediatric Research, 1992, 32, 505-508.	1.5	19
670	5 Fc-gamma receptors: mediators, targets and markers of disease. Best Practice and Research: Clinical Haematology, 1991, 4, 889-902.	1.0	4
671	Reactivity of cloned, expressed human FcγRIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcγRIII. International Immunology, 1990, 2, 303-310.	2.0	32
672	The Pi-linked receptor FcRIII is released on stimulation of neutrophils. Nature, 1988, 333, 667-669.	30.7	398
673	B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation. Annals of the Rheumatic Diseases, 0, 77, 955-958.	6.5	72
674	Improvement of microangiopathy after haematopoietic stem cell transplantation in systemic sclerosis. Clinical and Experimental Rheumatology, 0, , .	3.1	2
675	Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 0, , .	1.9	2
676	Ratio between biological and targeted synthetic disease-modifying anti-rheumatic drugs and glucocorticoid use in various countries: results from METEOR. Scandinavian Journal of Rheumatology, 0, 55, 38-45.	0.6	0
677	High Interleukin-10 Production in First-Degree Relatives of Patients with Generalized but Not Cutaneous Lupus Erythematosus. Journal of Investigative Medicine, 0, 48, 327-334.	0.9	0
678	Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens. Arthritis Research and Therapy, 0, 28, .	2.9	0
679	Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). Clinical Rheumatology, 0, , .	1.3	0
680	Is now the time for combination of targeted therapies in inflammatory arthritis?. Expert Review of Clinical Immunology, 0, , 1-3.	2.3	0